RxDoctor Payments Data

Danielle Besand

Family · O Fallon, MONPI 1932655479

Payments from drug & device makers

$2,478in general payments, 2019–2025

Across 143 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$849
  • Lilly USA, LLC$317
  • Novo Nordisk$282
  • Organon$173
  • AstraZeneca$131
  • Teva Pharmaceuticals USA, Inc.$116
  • plus $609 from 12 others

What the payments were for

  • Food & beverage$2,478100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,478 in reported general payments places this provider in the 80th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$18,365
Medicare patients
78
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin36$33,934
OzempicSemaglutide15$33,320
EliquisApixaban17$24,673
TrulicityDulaglutide14$15,111
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$12,330
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,990
LantusInsulin Glargine,hum.Rec.Anlog20$1,943
Pantoprazole Sodium52$916
Atorvastatin Calcium123$826
Duloxetine Hcl28$734
Bupropion XlBupropion Hcl25$690
Omeprazole39$665
Levothyroxine Sodium83$653
Gabapentin24$501
Lisinopril92$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$87$33,93436 claims
Novo NordiskOzempic$282$33,32015 claims
PfizerEliquis$53$24,67317 claims
Lilly USA, LLCTrulicity$317$15,11114 claims
AstraZenecaBreztri Aerosphere$131$12,33011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,812 family providers in Missouri.

Other family in O Fallon

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →